

IDSAP 2021 Book 1 (*Infections in Immunocompromised Patients*)

Release date: May 17, 2021

BCIDP test deadline: 11:59 p.m. (Central) on November 15, 2021.

ACPE test deadline: 11:59 p.m. (Central) on May 17, 2024.



Continuing Pharmacy Education Credit: The American College of Clinical Pharmacy

and the American Society of Health-System Pharmacists are accredited by the Accreditation Council for Pharmacy Education (ACPE) as providers of continuing pharmacy education (CPE).

IDSAP Target Audience: The target audience for IDSAP 2021 Book 1 (*Infections in Immunocompromised Patients*) is board-certified infectious diseases pharmacists caring patients with immune compromise and those involved in antimicrobial stewardship.

Module I (4.5 CPE) 0217-9999-21-019-H01-P

Chapter: Cytomegalovirus

Learning Objectives

1. Evaluate patients for pathogenesis and risk factors associated with cytomegalovirus (CMV) infection.
2. Develop plans for prophylaxis and preemptive therapy against CMV after solid organ transplant and hematopoietic stem cell transplant.
3. Design comprehensive treatment plans for patients with CMV infection and disease.
4. Develop a plan to detect and manage CMV treatment-related adverse effects and toxicities.

Chapter: Candidemia and Invasive Candidiasis

Learning Objectives

1. Design initial and step-down antifungal regimens for the treatment of candidemia and candidiasis based on anatomic location and severity.
2. Distinguish side effects and limitations of the common antifungals used in the management of candidemia and candidiasis.
3. Evaluate a patient for the proper initiation of empiric antifungal therapy for suspected invasive candidiasis.
4. Evaluate a patient for the need of antifungal prophylaxis to prevent candidiasis.

Module II (6.0 CPE) 0217-9999-21-020-H01-P

Chapter: Invasive Mold Infections

Learning Objectives

1. Design appropriate first-line, empiric treatment of invasive mold infections, accounting for clinical presentation, risk factors, patient characteristics, and antifungal pharmacology.

2. Distinguish the characteristics of antifungal agents according to their spectra of anti-mold activity, adverse effects, drug-drug interactions, and monitoring parameters.
3. Evaluate the role of prophylaxis against invasive mold infections in specialized patient populations, according to risk-versus-benefit analysis and supporting evidence.

Chapter: Evaluation of Antibiotic Allergies

Learning Objectives

1. Evaluate cellular and humoral components of the innate and adaptive immune responses.
2. Distinguish characteristics of immediate and delayed hypersensitivity reactions.
3. Evaluate features associated with an increased risk of drug hypersensitivity reactions.
4. Develop a management strategy for patients with antibiotic hypersensitivities.
5. Assess the rate of cross-reactivity between antibiotics with similar chemical structures.

Chapter: The Link Between Stewardship Strategies and Antimicrobial Resistance

Learning Objectives

1. Distinguish urgent, serious, and concerning threats using information in the CDC's Antibiotic Resistance Threats in the United States, 2019 report.
2. Evaluate immunocompromised patients for the characteristics and prevalence of multi-drug resistant infections.
3. Evaluate antimicrobial stewardship strategies and modalities for combating antimicrobial resistance in both the inpatient and outpatient settings.
4. Using knowledge of antimicrobial resistance and antimicrobial stewardship, develop a plan for reducing resistance.

Module III (5.5 CPE) UAN: 0217-9999-21-021-H01-P

Interactive case: Asymptomatic Bacteriuria

Learning Objectives

1. Distinguish the differences between asymptomatic bacteriuria (ASB) and a UTI.
2. Evaluate a patient and assess the need for treatment of ASB.
3. Assess a patient for the proper initiation of antibiotics for ASB.

Interactive case: Nocardia and Atypical Mycobacteria Infections

Learning Objectives

1. Distinguish the microbiology and pathophysiology of *Nocardia* and nontuberculous mycobacteria (NTM) infections.
2. Evaluate patients for clinical presentation and diagnostic criteria for *Nocardia* and NTM infections.
3. Design appropriate therapy regimens for patients with *Nocardia* and NTM infections.
4. Assess key pharmacotherapy monitoring values for therapies used for *Nocardia* and NTM infections.

Interactive case: Immunization in the Immunocompromised Host

Learning Objectives

1. Assess immunocompromised patients for preventable viral and bacterial pathogens with recent recurrence or outbreaks because of vaccine hesitancy that place them at high risk.
2. Evaluate the impact of risk factors and immunocompromising conditions relative to the timing and selection of vaccines (e.g., live, adjuvanted).
3. Evaluate the recent changes to adult vaccination and implications relative to the care of immunocompromised patients.